19 research outputs found
ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ ΠΎΠ»ΠΈ Ξ± Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠΈΠΌ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡΠΎΠΌ Π²ΠΎ Π²ΡΠ΅ΠΌΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ
Objective: to present our own experience of tumor necrosis factor Ξ± (TNFΞ±) inhibitors (iTNFΞ±) usage during pregnancy in women with ankylosing spondylitis (AS), to assess AS activity and outcomes of gestation.Patients and methods. A prospective observation of 55 pregnant women with AS who met the modified New York criteria of 1984. Fifty-six pregnancies were followed. The average age of the patients was 31.7Β±4.7 years, the duration of the disease was 132.2Β±85.4 months. The median BASDAI for pregnancy trimesters was 2.4 [1.2; 4.4], 2.7 [1.4; 4.2] and 2.2 [1.5; 4.0], respectively. 14 women received iTNFΞ± 3 months before pregnancy.Results and discussion. In the first trimester, TNFΞ± was used in 9 (16.1%) patients, in the second β in 9 (16.1%) and in the third β in 5 (9.3%); the median BASDAI for trimesters was 2.3 [1.0; 3.7], 3.4 [1.2; 3.5], 3.0 [0.8; 3.4], respectively. All patients who discontinued iTNFΞ± just before or in early pregnancy had indications for resuming therapy in the second half of gestation. Cancellation of iTNFΞ± at the end of the second trimester was not a risk factor for high activity in the third trimester. There was 1 adverse pregnancy outcome. In other cases, childbirth occurred at 38.9Β±1.4 weeks, newborns' body weight was 3273.1Β±435.6 g.Conclusion. Women with AS who plan a pregnancy should be prescribed drugs with the maximum allowed duration of use during gestation. Cancellation of iTNFΞ± before and in early pregnancy is a risk factor for high AS activity, while renewal of iTNFΞ± therapy during pregnancy is not always effective.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΎΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (ΠΈΠ€ΠΠΞ±) Π²ΠΎ Π²ΡΠ΅ΠΌΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠΈΠΌ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡΠΎΠΌ (ΠΠ‘), ΠΎΡΠ΅Π½ΠΈΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΠ‘ ΠΈ ΠΈΡΡ
ΠΎΠ΄Ρ Π³Π΅ΡΡΠ°ΡΠΈΠΈ.ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ 55 Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
Ρ ΠΠ‘, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΎΠ²Π°Π²ΡΠΈΡ
ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΠΡΡ-ΠΠΎΡΠΊΡΠΊΠΈΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ 1984 Π³. ΠΡΠΎΡΠ»Π΅ΠΆΠ΅Π½ΠΎ 56 Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠ΅ΠΉ. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΡΠΎΡΡΠ°Π²Π»ΡΠ» 31,7Β±4,7 Π³ΠΎΠ΄Π°, ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ β 132,2Β±85,4 ΠΌΠ΅Ρ. ΠΠ΅Π΄ΠΈΠ°Π½Π° BASDAI ΠΏΠΎ ΡΡΠΈΠΌΠ΅ΡΡΡΠ°ΠΌ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ β 2,4 [1,2; 4,4], 2,7 [1,4; 4,2] ΠΈ 2,2 [1,5; 4,0] ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ€ΠΠΞ± Π·Π° 3 ΠΌΠ΅Ρ Π΄ΠΎ Π½Π°ΡΡΡΠΏΠ»Π΅Π½ΠΈΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ 14 ΠΆΠ΅Π½ΡΠΈΠ½.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π I ΡΡΠΈΠΌΠ΅ΡΡΡΠ΅ ΠΈΠ€ΠΠΞ± ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ 9 (16,1%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ, Π²ΠΎ II β 9 (16,1%) ΠΈ Π² III β 5 (9,3%); ΠΌΠ΅Π΄ΠΈΠ°Π½Π° BASDAI ΠΏΠΎ ΡΡΠΈΠΌΠ΅ΡΡΡΠ°ΠΌ ΡΠΎΡΡΠ°Π²Π»ΡΠ»Π° 2,3 [1,0; 3,7], 3,4 [1,2; 3,5], 3,0 [0,8; 3,4] ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ, ΠΎΡΠΌΠ΅Π½ΠΈΠ²ΡΠΈΠ΅ ΠΈΠ€ΠΠΞ± Π½Π°ΠΊΠ°Π½ΡΠ½Π΅ ΠΈΠ»ΠΈ Π½Π° ΡΠ°Π½Π½ΠΈΡ
ΡΡΠΎΠΊΠ°Ρ
Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ, ΠΈΠΌΠ΅Π»ΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΠΊ Π²ΠΎΠ·ΠΎΠ±Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²ΠΎ Π²ΡΠΎΡΠΎΠΉ ΠΏΠΎΠ»ΠΎΠ²ΠΈΠ½Π΅ Π³Π΅ΡΡΠ°ΡΠΈΠΈ. ΠΡΠΌΠ΅Π½Π° ΠΈΠ€ΠΠΞ± Π² ΠΊΠΎΠ½ΡΠ΅ II ΡΡΠΈΠΌΠ΅ΡΡΡΠ° Π½Π΅ ΡΠ²Π»ΡΠ»Π°ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ° Π²ΡΡΠΎΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² III ΡΡΠΈΠΌΠ΅ΡΡΡΠ΅. ΠΠΌΠ΅Π» ΠΌΠ΅ΡΡΠΎ 1 Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ ΠΈΡΡ
ΠΎΠ΄ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ. Π ΠΎΡΡΠ°Π»ΡΠ½ΡΡ
ΡΠ»ΡΡΠ°ΡΡ
ΡΠΎΠ΄Ρ ΠΏΡΠΎΠΈΠ·ΠΎΡΠ»ΠΈ Π½Π° ΡΡΠΎΠΊΠ΅ 38,9Β±1,4 Π½Π΅Π΄, ΠΌΠ°ΡΡΠ° ΡΠ΅Π»Π° Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΡΡ
β 3273,1Β±435,6 Π³.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅Π½ΡΠΈΠ½Π°ΠΌ Ρ ΠΠ‘, ΠΏΠ»Π°Π½ΠΈΡΡΡΡΠΈΠΌ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΡ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ Π½Π°Π·Π½Π°ΡΠ°ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠΊΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²ΠΎ Π²ΡΠ΅ΠΌΡ Π³Π΅ΡΡΠ°ΡΠΈΠΈ. ΠΡΠΌΠ΅Π½Π° ΠΈΠ€ΠΠΞ± ΠΏΠ΅ΡΠ΅Π΄ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΡΡ ΠΈ Π½Π° Π΅Π΅ ΡΠ°Π½Π½ΠΈΡ
ΡΡΠΎΠΊΠ°Ρ
β ΡΠ°ΠΊΡΠΎΡ ΡΠΈΡΠΊΠ° Π²ΡΡΠΎΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΠ‘, ΠΏΡΠΈ ΡΡΠΎΠΌ Π²ΠΎΠ·ΠΎΠ±Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ€ΠΠΞ± Π²ΠΎ Π²ΡΠ΅ΠΌΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Π½Π΅ Π²ΡΠ΅Π³Π΄Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ
Π€Π΅Π±ΡΠΊΡΠΎΡΡΠ°Ρ Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠΎΠ΄Π°Π³ΡΡ: ΠΎΡ ΡΠ΅ΠΎΡΠΈΠΈ ΠΊ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅
Gout is a chronic disease that requires permanent urate-lowering therapy. Allopurinol is the gold standard of this therapy. The novel drug febuxostat, a selective xanthine oxidase inhibitor, has been synthesized and introduced into clinical practice in the last 10 years. The paper reviews the literature on the main clinical trials of febuxostat, which show its efficacy that is comparable to or more higher than that of allopurinol, as well as the possibility of using this drug for reduced kidney function, allergic reaction to allopurinol or resistance to therapy with allopurinol, which considerably improves prognosis in these patients. The long-term use of febuxostat is noted to result in almost complete resorption of tophi and in termination of gouty arthritis attacks. These findings allow febuxostat to be considered as a promising and essential medication for the treatment of gout. Great hopes are pinned on the extension of its application; there are ongoing investigations regarding the possibility of using this drug for asymptomatic hyperuricemia and other conditions accompanied by higher uric acid levels.Β ΠΠΎΠ΄Π°Π³ΡΠ° β Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, ΡΡΠ΅Π±ΡΡΡΠ΅Π΅ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎΠΉ ΡΡΠ°Ρ-ΡΠ½ΠΈΠΆΠ°ΡΡΠ΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Β«ΠΠΎΠ»ΠΎΡΡΠΌ ΡΡΠ°Π½Π΄Π°ΡΡΠΎΠΌΒ» ΡΠ°ΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°Π»Π»ΠΎΠΏΡΡΠΈΠ½ΠΎΠ». Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π³ΠΎ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ Π±ΡΠ» ΡΠΈΠ½ΡΠ΅Π·ΠΈΡΠΎΠ²Π°Π½ ΠΈ ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π² Π°ΡΡΠ΅Π½Π°Π»Π΅ Π²ΡΠ°ΡΠ΅ΠΉ Π½ΠΎΠ²ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ β ΡΠ΅Π±ΡΠΊΡΠΎΡΡΠ°Ρ, ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡ ΠΊΡΠ°Π½ΡΠΈΠ½ΠΎΠΊΡΠΈΠ΄Π°Π·Ρ. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΠΌ ΡΡΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, Π² ΠΊΠΎΡΠΎΡΡΡ
Π±ΡΠ»Π° ΠΏΠΎΠΊΠ°Π·Π°Π½Π° Π΅Π³ΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ, ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠ°Ρ ΠΈΠ»ΠΈ ΠΏΡΠ΅Π²ΡΡΠ°ΡΡΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π°Π»Π»ΠΎΠΏΡΡΠΈΠ½ΠΎΠ»Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠ΅ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΅Π³ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ ΠΏΠΎΡΠ΅ΠΊ, Ρ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ΅ΠΉ Π½Π° Π°Π»Π»ΠΎΠΏΡΡΠΈΠ½ΠΎΠ» ΠΈΠ»ΠΈ ΠΆΠ΅ Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡΡ ΠΊ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π»Π»ΠΎΠΏΡΡΠΈΠ½ΠΎΠ»ΠΎΠΌ, ΡΡΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ»ΡΡΡΠ°Π΅Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ· Ρ ΡΠ°ΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΠΏΡΠΈΠ΅ΠΌΠ΅ ΡΠ΅Π±ΡΠΊΡΠΎΡΡΠ°ΡΠ° Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ»Π½ΠΎΠ΅ ΡΠ°ΡΡΠ°ΡΡΠ²Π°Π½ΠΈΠ΅ ΡΠΎΡΡΡΠΎΠ² ΠΈ ΠΏΡΠ΅ΠΊΡΠ°ΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π°ΡΠ°ΠΊ ΠΏΠΎΠ΄Π°Π³ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΡΡΡΠΈΡΠ°. ΠΡΠ΅ ΡΡΠΈ ΡΠ°ΠΊΡΡ Π΄Π΅Π»Π°ΡΡ ΡΠ΅Π±ΡΠΊΡΠΎΡΡΠ°Ρ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎΠ΄Π°Π³ΡΡ.
ΠΡΡΠ΅ΠΎΠ½Π΅ΠΊΡΠΎΠ·. Π§Π°ΡΡΡ 2. ΠΠ»ΠΈΠ½ΠΈΠΊΠ° ΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π°Π²Π°ΡΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π½Π΅ΠΊΡΠΎΠ·Π°
The paper describes the major clinical manifestations of osteonecrosis (ON), considers methods for its radiodiagnosis, and characterizes changes depending on the stage of ON. Different classifications of this process are presented.Π ΡΡΠ°ΡΡΠ΅ ΠΎΠΏΠΈΡΠ°Π½Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΎΡΡΠ΅ΠΎΠ½Π΅ΠΊΡΠΎΠ·Π° (ΠΠ), ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΌΠ΅ΡΠΎΠ΄Ρ Π΅Π³ΠΎ Π»ΡΡΠ΅Π²ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ ΠΎΡ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠ°Π΄ΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ°. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΠ
Evaluation of the efficiency of the regional project of the Sverdlovsk region "Fight against oncological diseases" on the example of breast cancer
The purpose of the study is to evaluate the effectiveness of the regional project "Fight against cancer in the Sverdlovsk region" using the example of breast cancer.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅Π³ΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΅ΠΊΡΠ° Β«ΠΠΎΡΡΠ±Π° Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ Π² Π‘Π²Π΅ΡΠ΄Π»ΠΎΠ²ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈΒ» Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Studying the effect of combination of metotrexat and hepatoprotectors on urine indicators in experiment on white laboratory rats
The article presents the results of an experiment in which the effect of the use of methotrexate and hepatoprotectors on laboratory parameters of urine, mortality, as well as the general condition of laboratory rats on dynamic body weight indicators compared with methotrexate monotherapy and the introduction of physiological protein was tested.Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°, Π² Ρ
ΠΎΠ΄Π΅ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΠΏΡΠΎΠ²Π΅ΡΡΠ»ΠΎΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠ° ΠΈ Π³Π΅ΠΏΠ°ΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡΠΎΠ² Π½Π° Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΌΠΎΡΠΈ, Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠ±ΡΠ΅Π΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΊΡΡΡ ΠΏΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠΎΠΌ ΠΈ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ°
Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ Π³ΠΈΠΏΠ΅ΡΡΡΠΈΠΊΠ΅ΠΌΠΈΠΈ Ρ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ² ΠΈ Π΅Π΅ ΡΠΎΠ»Ρ Π² Π³Π΅Π½Π΅Π·Π΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ ΠΈ ΠΎΠ±ΠΌΠ΅Π½Π½ΡΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ
In recent decades, the prevalence of hyperuricemia (HU) is increasing worldwide; the role of uric acid (UA) in the genesis of various metabolic disorders, cardiovascular diseases, and kidney disease is being discussed. There are very few investigations of the rate of HU and its role in the development of diseases in certain social groups, including in professional athletes.Objective: to estimate the prevalence of HU and its role in the genesis of various pathological conditions and metabolic disturbances in professional athletes.Patients and methods. A retrospective comparative one-stage study was conducted, for which 2148 athletes who met inclusion criteria were selected and examined in the Federal Research and Clinical Center for Sports Medicine and Rehabilitation, Federal Biomedical Agency, in 2015. A control group consisted of 99 ageand sex-matched healthy volunteers examined at the V.A. Nasonova Research Institute of Rheumatology in 2017. The analysis included a comparison of the rate of HU and other examined parameters in professional athletes and healthy volunteers. The examined parameters were separately compared in athletes with/without HU, followed by statistical processing of results.Results. HU was detected in 306 (14.2%) of the 2148 athletes, more often in men (n=253 (20%) than in women (n=53 (6%); (p<0.001). The rate of HU in the athletes was comparable with that in the healthy population (12.1%). The athletes with HU (n=306) compared with the other athletes (n=1842) had the following statistically higher indicators: the mean serum levels of creatinine, triglycerides, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltranspeptidase, creatinine phosphokinase, and myoglobin, glomerular filtration rate, and body mass index (BMI) (p<0.00001 for all cases).Conclusion. HU is detected quite often in professional athletes (14.2%), which is comparable with the indicators seen in healthy volunteers (12.1%). The high prevalence of HU and its association with indicators reflecting kidney function, lipid metabolic disturbances, and BMI necessitate further investigations aimed at searching the causes of HU and methods of its prevention and treatment in professional athletes.Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ Π³ΠΈΠΏΠ΅ΡΡΡΠΈΠΊΠ΅ΠΌΠΈΠΈ (ΠΠ£) Π² ΠΌΠΈΡΠ΅ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅ΡΡΡ, ΠΎΠ±ΡΡΠΆΠ΄Π°Π΅ΡΡΡ ΡΠΎΠ»Ρ ΠΌΠΎΡΠ΅Π²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ (ΠΠ) Π² Π³Π΅Π½Π΅Π·Π΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΎΠ±ΠΌΠ΅Π½Π½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ, ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π±ΠΎΠ»Π΅Π·Π½Π΅ΠΉ ΠΏΠΎΡΠ΅ΠΊ. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΡ
ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΠ°ΡΡΠΎΡΡ ΠΠ£ ΠΈ Π΅Π΅ ΡΠΎΠ»ΠΈ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Π² ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Ρ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ², ΠΊΡΠ°ΠΉΠ½Π΅ ΠΌΠ°Π»ΠΎ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΠ£ ΠΈ Π΅Π΅ ΡΠΎΠ»ΠΈ Π² Π³Π΅Π½Π΅Π·Π΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ, ΠΎΠ±ΠΌΠ΅Π½Π½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Ρ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ².ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΎΠ΄Π½ΠΎΠΌΠΎΠΌΠ΅Π½ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, Π΄Π»Ρ ΡΡΠ°ΡΡΠΈΡ Π² ΠΊΠΎΡΠΎΡΠΎΠΌ ΠΎΡΠΎΠ±ΡΠ°Π½Ρ 2148 ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ², ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ, ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° Π±Π°Π·Π΅ Π€ΠΠΠ£ Β«Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΡΠΉ Π½Π°ΡΡΠ½ΠΎ-ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ΅Π½ΡΡ ΡΠΏΠΎΡΡΠΈΠ²Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΈ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄ΠΈΠΊΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π³Π΅Π½ΡΡΡΠ²Π°Β» Π² 2015 Π³. ΠΡΡΠΏΠΏΡ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 99 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π², ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΡΡ
ΠΏΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΡ ΠΈ ΠΏΠΎΠ»Ρ, ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° Π±Π°Π·Π΅ Π€ΠΠΠΠ£ ΠΠΠΠ ΠΈΠΌ. Π.Π. ΠΠ°ΡΠΎΠ½ΠΎΠ²ΠΎΠΉ Π² 2017 Π³. ΠΠ½Π°Π»ΠΈΠ· Π²ΠΊΠ»ΡΡΠ°Π» ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ ΠΠ£ ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² Ρ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ² ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π². ΠΡΠ΄Π΅Π»ΡΠ½ΠΎ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Ρ ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ² Ρ/Π±Π΅Π· ΠΠ£ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΉ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠΎΠΉ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ².Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ£ Π²ΡΡΠ²Π»Π΅Π½Π° Ρ 306 (14,2%) ΠΈΠ· 2148 ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ², ΡΠ°ΡΠ΅ Ρ ΠΌΡΠΆΡΠΈΠ½ (253, ΠΈΠ»ΠΈ 20%), ΡΠ΅ΠΌ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ (53, ΠΈΠ»ΠΈ 6%; p<0,001). Π§Π°ΡΡΠΎΡΠ° ΠΠ£ Ρ ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ² ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠΎΠΉ Ρ ΡΠ°ΠΊΠΎΠ²ΠΎΠΉ Π² Π·Π΄ΠΎΡΠΎΠ²ΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ (12,1%). Π£ ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ² Ρ ΠΠ£ (n=306) Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΠΎΡΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΡΠΏΠΎΡΡΡΠΌΠ΅Π½Π°ΠΌΠΈ (n=1842) ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π²ΡΡΠ΅ Π±ΡΠ»ΠΈ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ: ΡΡΠ΅Π΄Π½ΠΈΠ΅ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΡΠ΅ ΡΡΠΎΠ²Π½ΠΈ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π°, ΡΡΠΈΠ³Π»ΠΈΡΠ΅ΡΠΈΠ΄ΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ Π°ΡΠΏΠ°ΡΡΠ°ΡΠ°ΠΌΠΈΠ½ΠΎΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π·Ρ, Π°Π»Π°Π½ΠΈΠ½Π°ΠΌΠΈΠ½ΠΎΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π·Ρ, Π³Π°ΠΌΠΌΠ°-Π³Π»ΡΡΠ°ΠΌΠΈΠ»ΡΡΠ°Π½ΡΠΏΠ΅ΠΏΡΠΈΠ΄Π°Π·Ρ, ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ΡΠΎΡΡΠΎΠΊΠΈΠ½Π°Π·Ρ, ΠΌΠΈΠΎΠ³Π»ΠΎΠ±ΠΈΠ½Π°, ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΊΠ»ΡΠ±ΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ, ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° (ΠΠΠ’; Ρ<0,00001 Π΄Π»Ρ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°Π΅Π²).ΠΡΠ²ΠΎΠ΄Ρ. ΠΠ£ Ρ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ² Π²ΡΡΠ²Π»ΡΠ΅ΡΡΡ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΡΠ°ΡΡΠΎ (14,2%), ΡΡΠΎ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠΎ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π² (12,1%). ΠΡΡΠΎΠΊΠ°Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΠΠ£, Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ Π΅Π΅ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ, ΠΎΡΡΠ°ΠΆΠ°ΡΡΠΈΠΌΠΈ ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΡΠ΅ΠΊ, Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°, ΠΠΠ’ Π΄Π΅Π»Π°ΡΡ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΠΌΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΠ΅ Π½Π° ΠΏΠΎΠΈΡΠΊ ΠΏΡΠΈΡΠΈΠ½, ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠ£ Ρ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΏΠΎΡΡΡΠΌΠ΅Π½ΠΎΠ²
Private Trade in the Mixed Economy of the Urals under the NEP
The article was submitted on 15.12.2019.Review of: Kilin, A. P. (2018). Chastnaya torgovlya i kredit na Urale v gody nepa: ekonomicheskie, politicheskie i sotsialβnye aspekty [Private Trade and Credit in the Urals under the NEP: Economic, Political, and Social Aspects]. Yekaterinburg, Izdatelβstvo Uralβskogo universiteta. 606 p. The author reviews Private Trade and Credit in the Urals under the NEP: Economic, Political, and Social Aspects: A Monograph by A. P. Kilin, which focuses on the topic of private trade under the NEP and considers it in a wider chronological context. The monograph analyses the NEP as a model of managing and regulating the economy, trade, and commodity turnover in the Urals. It also considers private trade as an object of state control, the credit system, social aspects of private enterprise under the NEP and the trading and intermediary activities of workers. The monograph provides a heterogeneous picture which enables the reader to gain a comprehensive idea of the NEP and the place private trade occupied in it. Of crucial historiographic importance is the authorβs conclusion that private trade was an organic part of the mixed economyβs structure under the NEP and served to connect the producer, the consumer, different spheres of economy and economic setups.Π Π΅ΡΠ΅Π½Π·ΠΈΡ Π½Π° ΠΊΠ½ΠΈΠ³Ρ: ΠΠΈΠ»ΠΈΠ½ Π. Π. Π§Π°ΡΡΠ½Π°Ρ ΡΠΎΡΠ³ΠΎΠ²Π»Ρ ΠΈ ΠΊΡΠ΅Π΄ΠΈΡ Π½Π° Π£ΡΠ°Π»Π΅ Π² Π³ΠΎΠ΄Ρ ΠΠΠΠ°: ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅, ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ. ΠΠΊΠ°ΡΠ΅ΡΠΈΠ½Π±ΡΡΠ³: ΠΠ·Π΄Π°ΡΠ΅Π»ΡΡΡΠ²ΠΎ Π£ΡΠ°Π»ΡΡΠΊΠΎΠ³ΠΎ ΡΠ½ΠΈΠ²Π΅ΡΡΠΈΡΠ΅ΡΠ°, 2018. 606 Ρ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΌΠΎΠ½ΠΎΠ³ΡΠ°ΡΠΈΠΈ Π. Π. ΠΠΈΠ»ΠΈΠ½Π° Β«Π§Π°ΡΡΠ½Π°Ρ ΡΠΎΡΠ³ΠΎΠ²Π»Ρ ΠΈ ΠΊΡΠ΅Π΄ΠΈΡ Π½Π° Π£ΡΠ°Π»Π΅ Π² Π³ΠΎΠ΄Ρ ΠΠΠΠ°: ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅, ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡΒ». Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ΅ΠΌΠ°ΡΠΈΠΊΠ° ΡΠ°ΡΡΠ½ΠΎΠΉ ΡΠΎΡΠ³ΠΎΠ²Π»ΠΈ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΠΠΠ° Π²ΡΡΡΠΎΠ΅Π½Π° Π² Π±ΠΎΠ»Π΅Π΅ ΡΠΈΡΠΎΠΊΠΈΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ½ΡΠΉ ΠΈ Ρ
ΡΠΎΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΊΠΎΠ½ΡΠ΅ΠΊΡΡ. Π ΠΌΠΎΠ½ΠΎΠ³ΡΠ°ΡΠΈΠΈ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ Π°Π½Π°Π»ΠΈΠ· Π½ΠΎΠ²ΠΎΠΉ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠΈΠΊΠΈ ΠΊΠ°ΠΊ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΈ ΡΠ΅Π³ΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΊΠΈ, ΡΠΎΡΠ³ΠΎΠ²Π»ΠΈ ΠΈ ΡΠΎΠ²Π°ΡΠΎΠΎΠ±ΠΎΡΠΎΡΠ° Π½Π° Π£ΡΠ°Π»Π΅, ΡΠ°ΡΡΠ½ΠΎΠΉ ΡΠΎΡΠ³ΠΎΠ²Π»ΠΈ ΠΊΠ°ΠΊ ΠΎΠ±ΡΠ΅ΠΊΡΠ° Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠ΅Π³ΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, ΠΊΡΠ΅Π΄ΠΈΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, ΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΡ
Π°ΡΠΏΠ΅ΠΊΡΠΎΠ² ΡΠ°ΡΡΠ½ΠΎΠΏΡΠ΅Π΄ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΠ΅Π»ΡΡΠΊΠΎΠΉ Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΠΠΠ°, ΡΠΎΡΠ³ΠΎΠ²ΠΎ-ΠΏΠΎΡΡΠ΅Π΄Π½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ°ΠΊΡΠΈΠΊ ΡΠ°Π±ΠΎΡΠΈΡ
. Π ΠΊΠ½ΠΈΠ³Π΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΌΠΎΠ·Π°ΠΈΡΠ½Π°Ρ ΠΊΠ°ΡΡΠΈΠ½Π°, ΠΊΠΎΡΠΎΡΠ°Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠΈΡΠ°ΡΠ΅Π»Ρ ΠΏΠΎΠ»ΡΡΠΈΡΡ ΡΠ΅ΠΏΡΠ΅Π·Π΅Π½ΡΠ°ΡΠΈΠ²Π½ΠΎΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΎ ΠΠΠΠ΅ ΠΈ ΠΌΠ΅ΡΡΠ΅ Π² Π½Π΅ΠΌ ΡΠ°ΡΡΠ½ΠΎΠΉ ΡΠΎΡΠ³ΠΎΠ²Π»ΠΈ. ΠΡΡΠΎΡΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠ΅Π΅Ρ Π²ΡΠ²ΠΎΠ΄ Π°Π²ΡΠΎΡΠ°, ΡΡΠΎ ΡΠ°ΡΡΠ½Π°Ρ ΡΠΎΡΠ³ΠΎΠ²Π»Ρ ΠΎΡΠ³Π°Π½ΠΈΡΠ΅ΡΠΊΠΈ Π²ΠΏΠΈΡΡΠ²Π°Π»Π°ΡΡ Π² ΡΡΡΡΠΊΡΡΡΡ Π½ΡΠΏΠΎΠ²ΡΠΊΠΎΠΉ ΠΌΠ½ΠΎΠ³ΠΎΡΠΊΠ»Π°Π΄Π½ΠΎΠΉ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΊΠΈ, ΡΠ»ΡΠΆΠΈΠ»Π° ΡΠ²ΡΠ·ΡΡΡΠΈΠΌ Π·Π²Π΅Π½ΠΎΠΌ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»ΡΠΌΠΈ ΠΈ ΠΏΠΎΡΡΠ΅Π±ΠΈΡΠ΅Π»ΡΠΌΠΈ, ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΡΠ΅ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΊΠΈ ΠΈ Ρ
ΠΎΠ·ΡΠΉΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΡΠΊΠ»Π°Π΄Π°ΠΌΠΈ
Febuxostat in the therapy of gout: from theory to practice
Gout is a chronic disease that requires permanent urate-lowering therapy. Allopurinol is the gold standard of this therapy. The novel drug febuxostat, a selective xanthine oxidase inhibitor, has been synthesized and introduced into clinical practice in the last 10 years. The paper reviews the literature on the main clinical trials of febuxostat, which show its efficacy that is comparable to or more higher than that of allopurinol, as well as the possibility of using this drug for reduced kidney function, allergic reaction to allopurinol or resistance to therapy with allopurinol, which considerably improves prognosis in these patients. The long-term use of febuxostat is noted to result in almost complete resorption of tophi and in termination of gouty arthritis attacks. These findings allow febuxostat to be considered as a promising and essential medication for the treatment of gout. Great hopes are pinned on the extension of its application; there are ongoing investigations regarding the possibility of using this drug for asymptomatic hyperuricemia and other conditions accompanied by higher uric acid levels
RISK FACTORS FOR THE DEVELOPMENT OF LEFT VENTRICULAR MYOCARDIAL HYPERTROPHY IN PATIENTS WITH GOUT
Objective β to evaluate potential input of different factors in the development of left ventricular hypertrophy (LVH) in patients with gout. Material and methods. 57 male patients with gout were included into the study. Echocardiography was performed in M- and B-modes and left ventricular myocardial mass index (LVMMI) was calculated for each patient. LVH was defined as LVMMI >115 g/m 2. Results. LVH was detected in 23 (40,4%) out of 57 patients. LVH was associated with advanced age, arterial hypertension, obesity, hyperuricemia and increased C-reactive protein levels
Osteonecrosis. Part 2. The clinical picture and diagnosis of avascular necrosis
The paper describes the major clinical manifestations of osteonecrosis (ON), considers methods for its radiodiagnosis, and characterizes changes depending on the stage of ON. Different classifications of this process are presented